Great Diamond Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Great Diamond Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4	Closed	–	–	666
2019 Q4	$0	Buy	+4	New	+$428	﹤0.01%	684

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Great Diamond Partners's ALXN Position: Q1 2020 in Review

Great Diamond Partners sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 4 shares.

Great Diamond Partners first reported a position in ALXN in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

Great Diamond Partners reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Great Diamond Partners sold 4 Alexion Pharmaceuticals shares in Q1 2020.
Great Diamond Partners first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 1 quarter.
Great Diamond Partners's Alexion Pharmaceuticals position peaked at $0 in Q4 2019.
653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Great Diamond Partners's 13F filing for Q1 2020, filed 1 May 2020.